CDR-Life Appoints Pascal Touchon to the Board of Directors to Support Continued Growth and Advancement of Next Generation T Cell Engager Platform
CDR-Life today announced the appointment of Pascal Touchon, DVM, MBA, to its Board of Directors. Dr. Touchon brings 40 years of international experience in the biopharmaceutical industry, with extensive expertise in oncology and strategic leadership that will further strengthen CDR-Life as it advances its innovative M-gager® platform and pipeline of T cell engager (TCE) therapeutics.
CDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025
CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations showcase the company's proprietary M-gager® platform-derived TCE candidates, with a focus on CDR404, currently in Phase 1 clinical trials for MAGE-A4-positive solid tumors.
CDR-Life Demonstrates Commitment to Differentiated Pipeline with New Autoimmune Candidate CDR111
CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, Illinois.
CDR-Life Announces Fifth Milestone Achievement with Boehringer Ingelheim in Geographic Atrophy
CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716, a novel therapeutic candidate for the treatment of geographic atrophy (GA), a leading cause of vision loss.
CDR-Life Appoints Sarah Holland, PhD, as Chief Business Officer
CDR-Life today announced the appointment of Sarah Holland, PhD, as Chief Business Officer. Drawing on her over 30 years of biopharmaceutical industry expertise, Dr. Holland will spearhead CDR-Life’s business development initiatives and commercial strategy, focusing on advancing its innovative M-gager® platform to develop T cell engager (TCE) therapies for patients with cancer and autoimmune diseases.
CDR-Life Announces Pipeline Progress of M-gager® Programs for Treatment of Solid Tumors
CDR-Life today announced significant clinical progress in its M-gager® portfolio for solid tumors, marking important milestones in the company’s mission to deliver innovative, antibody-fragment based immunotherapies for difficult-to-treat cancers.
